Overview of Vitiligo Research July - September 2013

This is a VR Foundation’s regular review of research results in the vitiligo field which were indexed in the PubMed database (www.ncbi.nlm.nih.gov/pubmed) for the period from July 2013 till September 2013. Abstracts of papers were retrieved from the PubMed database using the search term “vitiligo” with a filter set up to retrieve records with creation date between July 01, 2013 and September 30, 2013. Retrieved records were manually checked for a relevance to and significance for the field of vitiligo research. Forty seven records have been selected for inclusion into this quarterly overview.


  • Broad-band UVA phototherapy reported to be superior over narrow-band UVB treatment
  • Foam formulation of clobetasol propionate may provide additional benefits in vitiligo treatment
  • Additional evidence of regulatory T-cell role in vitiligo provided
  • Sunscreen cream with bandpass centered at 311 nm has been described as a novel anti-vitiligo weapon
  • Lesional keratinocytes might be deficient in NB-UVB response thus contributing to failure of phototherapy in repigmentation
  • Every eighth patients treated with oral mini-pulse dexamethasone therapy to stop vitiligo progression will relapse at average of about 2.5 years after successful treatment
  • Rituximab, anti-CD20 recombinant monoclonal antibody, may be efficient in vitiligo treatment

Full report is available for download in pdf

image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

To download this free file, please tell us a little bit about yourself.